Company intelligence / Profile preview

Yissum

Jerusalem, Jerusalem District, Israelyissum.co.il ↗

Ownership: Private
Development stage: Other

Overview

Yissum has enabled the commercialization of over $2 billion in annual sales from products based on Hebrew University technology. Major successes include blockbuster drugs such as doxorubicin liposome ("Doxil"), rivastigmine ("Exelon"), cherry tomatoes in agriculture, Mobileye in automotive safety tech, among others. The company supports early-stage research through venture funds and has spun off more than 150 companies since its founding.

Therapeutic areas: OncologyMetabolic DisordersImmunologyOtherNeurologyWomen's Health
Modalities: Small moleculeBiologicDevicePeptidesCell therapy
Industry: Investors

Partnerships

Johnson & Johnson/JanssenNovartisTeva Pharmaceuticals

Beyond the preview

Go deeper on Yissum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yissum.

Explore the full profile